Impedimed Limited (ASX:IPD)


right-arrow Created with Sketch. -0.005 (-2.86%)
MCAP $301.8M
Last trade 16.10pm 26/11/2021 20mins delayed

Latest Announcements

23/11/2021IPDImpedimed Limited
22/11/2021IPDImpedimed Limited
18/11/2021IPDImpedimed Limited
18/11/2021 Price SensitivePSIPDImpedimed Limited
18/11/2021IPDImpedimed Limited
16/11/2021IPDImpedimed Limited
16/11/2021IPDImpedimed Limited
16/11/2021IPDImpedimed Limited

Company Overview

ImpediMed Limited is an Australia-based company, which is engaged in designing and manufacturing of medical devices. The Company develops various medical products that use bioimpedance spectroscopy (BIS) to measure and monitor fluid status and tissue composition. Its product includes SOZO Digital Health Platform. It is a non-invasive BIS device delivers a snapshot of fluid status and tissue composition in approximately 30 seconds. The Company’s SOZO Applications offer clinicians deeper insights into a patient’s health. SOZO Applications include various software applications, such as L-Dex Analysis for Lymphedema, Body Composition Analysis, Segmental Analysis and HF-Dex Analysis for Heart Failure. The Company’s research devices include SFB7 and ImpediVET. SFB7 single channel, tetrapolar BIS device, which measures fluid status and tissue composition for clinical and research applications.

IPD in the news

ImpediMed (IPD) completes its share purchase plan, heavily oversubscribed by more than…
ImpediMed (IPD) agrees to supply additional SOZO units to AstraZeneca (AZ) via…
ImpediMed (IPD) has rounded off its PREVENT trial, successfully meeting its primary…

Search Previous Announcements